Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Long-Term Deferred Tax (2023 - 2024)

Historic Long-Term Deferred Tax for Crinetics Pharmaceuticals (CRNX) over the last 2 years, with Q4 2024 value amounting to $291.5 million.

  • Crinetics Pharmaceuticals' Long-Term Deferred Tax rose 4975.4% to $291.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $291.5 million, marking a year-over-year increase of 4975.4%. This contributed to the annual value of $291.5 million for FY2024, which is 4975.4% up from last year.
  • Crinetics Pharmaceuticals' Long-Term Deferred Tax amounted to $291.5 million in Q4 2024, which was up 4975.4% from $194.7 million recorded in Q4 2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $291.5 million in Q4 2024 and a low of $194.7 million during Q4 2023